Trial Search Results

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Robert Negrin

Collaborator: National Institutes of Health (NIH)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cytokine Induced Killer Cells

Phase:

Phase 1

Eligibility


Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following
HLA matched allogeneic hematopoietic cell transplant

   - eligible for DLI

   - no evidence of GVHD

   - stable immunosuppressive regimen

   - adequate renal and liver function

Exclusion Criteria:- CML patients who have not received DLI, active infections

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822
Not Recruiting